Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023…
Ad hoc announcement pursuant to Art. 53 LRSupplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023H1 results demonstrated continued momentum with strong sales growth; full-year 2023 guidance confirmedSandoz Spin-off planned to occur on or around October 4, 2023 Basel, September 5, 2023— Sandoz today published a supplement to its Listing Prospectus of August 18, 2023, ahead of an Extraordinary General Meeting (EGM) of...
Nasdaq GlobeNewswire
05/09/2023
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
Cohort 1 is completed , and Cohort 2 is 80% recruited Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland,September 5 , 2023 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the ADX71149 (JNJ-40411813) Phase 2 epilepsy clinical study is progressing well, with Cohort 1 completed and 80% of patients recruited into Cohort 2...
Nasdaq GlobeNewswire
05/09/2023
Economist Impact report, Advancing the frontier of health and technology…
"We are confident that these insights will stimulate robust discussions about how to best integrate innovative digital technologies into healthcare systems," said Moritz Hartmann, Global Head, Roche Information Solutions at Roche Diagnostics. "We work with labs and hospitals around the world to bring them the latest digital health technologies and we know the importance of inclusive stakeholder collaboration and designing with healthcare professionals and patient needs in…
PR Newswire
05/09/2023
Sabin Vaccine Institute Leads Public and Private Sector Fight to Prevent HPV and…
“We are building a new ecosystem in global public health,” said Anuradha Gupta, President of Global Immunization at Sabin. “We aim to create and implement a strategic roadmap focused on improving access and adoption of the tools in our HPV prevention arsenal – vaccines, screening, and treatment of precancerous lesions.”Cervical cancer affects more than 600,00 women each year. It kills approximately 350,000 women annually, is increasing in frequency, and is highly preventable with the HPV...
Nasdaq GlobeNewswire
05/09/2023
Allergic Conjunctivitis Market is Expected to Showcase a Significant Growth by…
Key Takeaways from the Allergic Conjunctivitis Market Report Key Takeaways from the Allergic Conjunctivitis Market Report Discover which therapies are expected to grab the major allergic conjunctivitis market share @ Allergic Conjunctivitis Market Report Allergic Conjunctivitis Overview Allergic conjunctivitis is a common eye condition characterized by inflammation of the conjunctiva – the thin, transparent layer covering the white part of the eye and the inner surface of the eyelids...
PR Newswire
04/09/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary…
Company Announcement Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS)at predetermined , independent interim analysisTrial results to be submitted for presentation at a future medical meetingGenmab and Seagen to engage in discussions with regulatory authorities COPENHAGEN , Denmark , and BOTHELL, Wash.; September 4 , 2023 – Genmab A/S(Nasdaq:GMAB) andSeagen Inc.(Nasdaq:...
Nasdaq GlobeNewswire
04/09/2023
GN moves to “one company” governance structure; appoints Peter Karlstromer to…
The GN Group has a long and proud history as a technology innovator and, today, enjoys strong positions in attractive hearing, enterprise collaboration, and consumer gaming markets. In recent years, GN has increasingly expanded collaboration and integration across its two business divisions, GN Hearing and GN Audio, thus benefitting from joint innovation and leveraging combined scale to drive growth and profitability. GN's Board of Directors has now decided to execute the next step of...
Nasdaq GlobeNewswire
04/09/2023
Vaccine Adjuvants Market worth $1.2 billion | MarketsandMarkets
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894 Browse in-depth TOC on "Vaccine Adjuvants Market" 200 - Tables 45 - Figures 230 - Pages Vaccine Adjuvants Market Scope: The adjuvant emulsions segment is expected to have the dominant share of the vaccine adjuvants market in 2022: Based on product, the global...
PR Newswire
04/09/2023
Seegene Unveils 'Open Innovation Program Powered by Seegene' in Partnership with…
The inaugural 'Open Innovation Program' consists of 15 projects to develop 15 syndromic qPCR diagnostics assay reagents across infectious and vector-borne diseases, as well as in the detection of drug-resistant pathogens. Applications may be submitted by Oct. 31, 2023 (11:59 PM, GMT), and following a comprehensive assessment of applications, awardees will be announced on March 15, 2024. Applicants must comprise teams of two or more individuals employed or affiliated with a university, research…
PR Newswire
04/09/2023
Game-changing Virtuoso Digital Front Door technology radically rewires…
Digital Front Doors (DFD) will rewire health systems globally and Orion Health's DFD, Virtuoso, sets a new benchmark in improving the healthcare experience for all. Digital Front Doors (DFD) will rewire health systems globally and Orion Health's DFD,Virtuoso, sets a new benchmark in improving the healthcare experience for all. Virtuoso is already serving 15 million people inNorth America. It helps to engage people in their own healthcare journey whilst supporting health systems'...
PR Newswire
04/09/2023
Novo Nordisk A/S - share repurchase programme
Bagsværd , Denmark, 4September 2023– On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023...
Nasdaq GlobeNewswire
04/09/2023
Report of transactions of shares and related securities of Bavarian Nordic by…
COPENHAGEN, Denmark, September 4, 2023– Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NameLuc Debruyne 2.Reason for the notification a)Position/statusChairman of the Board of...
Nasdaq GlobeNewswire
04/09/2023
Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval…
SEPTEMBER 4, 2023On December 12, 2022, Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") announced that Novozymes and Chr. Hansen propose to combine and create a leading global biosolutions partner by way of a statutory merger of the two companies. Reference is made to Chr. Hansen's company announcement no. 13 of December 12, 2022.The Chinese State Administration for Market Regulation (SAMR) has now unconditionally approved the statutory merger of…
Nasdaq GlobeNewswire
04/09/2023
Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval…
Please read the announcement in PDF Attachment 2023_Chinese_merger_approval_granted
Nasdaq GlobeNewswire
04/09/2023
CBD Pouches Market to Reach $721.8 Million, Globally, by 2032 at 18.9% CAGR…
Request Sample of the Report on CBD Pouches Market Forecast 2032- Allied Market Research- https://www.alliedmarketresearch.com/request-sample/157137 Request Sample of the Report on CBD Pouches Market Forecast 2032- Allied Market Research-https://www.alliedmarketresearch.com/request-sample/157137 Prime Determinants of Growth The growing demand for CBD products and the rising awareness about the potential health benefits of CBD are predicted to be the important factors to boost the...
PR Newswire
04/09/2023
Oncorena's first patient treated with ONC175 (orellanine) in clinical phase I/II…
The clinical study, Oncorella-1, is conducted at the Center for Clinical Cancer Studies at Karolinska University Hospital, Stockholm, Sweden. Hemodialysis is given at the same hospital, since patients eligible to the study are dialysis-dependent. Now, the first patient was given an infusion of ONC175 for 30 minutes. Additional patients are ready for treatment in the autumn. Each patient is followed up four weeks after the infusion by an independent Data Review Committee recommending potential…
PR Newswire
04/09/2023
PCI Biotech: Employee share option scheme
In accordance with the authorisation granted by the Annual General Meeting 25 May 2023 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 700,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech's choice), at a strike price of NOK 1.66, equal to the volume weighted average share price (VWAP)...
Nasdaq GlobeNewswire
04/09/2023
BBS-Bioactive Bone Substitutes has resolved on a share issue without…
BBS-Bioactive Bone Substitutes Plc, Company announcement, 4 September 2023 at 09.45 a.m. EETBBS-Bioactive Bone Substitutes has resolved on a share issue without consideration to the company itself BBS-Bioactive Bone Substitutes Plc's Board of Directors has decided on 3 September 2023 to issue 500,000 shares without consideration to the company itself, for potential loan conversions as well as for other possible purposes, in accordance with authorisation from the Extraordinary...
Nasdaq GlobeNewswire
04/09/2023
24 000 Orion Corporation A shares converted into B shares
ORION CORPORATIONSTOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 4 SEPTEMBER 2023 at 9.30 EEST 24 000Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 24 000 A shares have been converted into 24 000 B shares. The conversion has been entered into the Trade Register on 4 September 2023.The total number of shares in Orion Corporation is 141,134,278...
Nasdaq GlobeNewswire
04/09/2023
SciBase strengthens US team with experienced Dermatology executive
With more than 24 years of experience in the US healthcare market, Dan has held leadership roles in Sales, Training, Commercial Operations, Commercial Insights, Key Accounts, Market Access, and Field Reimbursement. His experience building winning teams within the US Dermatology market, and deep knowledge of the US medical benefit reimbursement landscape, will be key in driving SciBase US sales and market access activities forward. With more than 24 years of experience in the US healthcare...
PR Newswire
04/09/2023
Mendus to participate in multiple investor and industry conferences in September
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: H.C. Wainwright 25th Annual Global Investment Conference New York, USA, September 11-13, 2023Mendus CEO Erik Manting will participate and present a Company Update at the conference: https://hcwevents.com/annualconference/ Pareto Securities' Annual Healthcare...
Nasdaq GlobeNewswire
04/09/2023
Addex's Dipraglurant Development in Post-Stroke Recovery Supported by Data…
Landmark study shows mGlu5 receptor negative allosteric modulators (NAMs) restore lost neurological functionsFirst time mGlu5 linked to post-stroke functional recovery Ad Hoc Announcement Pursuant to Art. 53 LRGeneva, Switzerland, September 4, 2023 - Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that data published inBrain...
Nasdaq GlobeNewswire
04/09/2023
Ipsen nominates Pascal Touchon to its Board of Directors as new independent…
PARIS, FRANCE,4 September 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today the co-optation of Pascal Touchon to its Board as an independent director, effective 4 October 2023, following the decision of Paul Sekhri to step down from his director role on this date due to other professional commitments. Pascal Touchon is an experienced biotech CEO and pharma leader and is the CEO of ATARA Biotherapeutics. He has previously held leadership positions at Novartis and Servier and has...
Nasdaq GlobeNewswire
04/09/2023
Coway's Air and Water Purifiers Recognized at IDEA 2023
In this year's edition, Coway achieved an impressive feat by garnering three awards: the 'Multi-Action Air Purifier 2 (AP-1523D)' was honored with the Silver award, the 'Icon Max Free Water Purifier (CHP-4600N)' gained the Bronze award, and the 'Skin Plus Water Softener (BB-16/17A)' earned notable recognition as a Finalist. In this year's edition, Coway achieved an impressive feat by garnering three awards: the 'Multi-Action Air Purifier 2 (AP-1523D)' was honored with the Silver award, the...
PR Newswire
04/09/2023
Altri Comunicati
